AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Shun Lu; Xiaorong Dong; Hong Jian; Jianhua Chen; Gongyan Chen; Yuping Sun; Yinghua Ji; Ziping Wang; Jianhua Shi; Junguo Lu; Shaoshui Chen; Dongqing Lv; Guojun Zhang; Chunling Liu; Juan Li; Xinmin Yu; Zhong Lin; Zhuang Yu; Zhehai Wang; Jiuwei Cui; Xingxiang Xu; Jian Fang; Jifeng Feng; Zhi Xu; Rui Ma; Jie Hu; Nong Yang; Xiangdong Zhou; Xiaohong Wu; Chengping Hu; Zhihong Zhang; You Lu; Yanping Hu; Liyan Jiang; Qiming Wang; Renhua Guo; Jianying Zhou; Baolan Li; Chunhong Hu; Wancheng Tong; Helong Zhang; Lin Ma; Yuan Chen; Zhijun Jie; Yu Yao; Longzhen Zhang; Weng Jie; Weidong Li; Jianping Xiong; Xianwei Ye; Jianchun Duan; Haihua Yang; Meili Sun; Changan Sun; Hongying Wei; Chuan Li; Siraj M Ali; Vincent A Miller; Qiong Wu